BACKGROUND: The aim of this study was to evaluate the impact of contact force (CF) visualization on the incidence of low and high CF during left atrial (LA) mapping and pulmonary vein isolation (PVI). METHODS: CF was assessed in 70 patients who underwent PVI. Three highly experienced operators performed all procedures. The operators were blinded to CF in group A (35 patients), and CF was displayed in group B (35 patients). In group B, optimal CF was defined as mean CF between 10 and 39g, and operators attempted to acquire points and ablate within this range. RESULTS: A total of 8401 mapping points were analyzed during LA mapping (group A: 4104, group B: 4297). Low CF <10g and high CF ≥40g were noted in a significantly larger number of points in group A (37.7 vs. 12.0 %, P < 0.001; 11.5 vs. 1.5 %, P < 0.001). At the mitral isthmus and ridge areas, CF was significantly lower (7.7 vs. 12.2g, P < 0.001; 5.3 vs. 11.7g, P < 0.001) in group A than in group B. PVI was successfully achieved in all patients. There were significant site-dependent CF differences between the two groups. Optimal CF was achieved in significantly more applications in group B (P < 0.001). There was no significant difference in atrial fibrillation (AF) recurrence rates after a minimum follow-up of 1 year between the two groups in this cohort (P = 0.24). No significant peri-procedural complications occurred in either group. CONCLUSIONS: CF visualization can assist in avoiding both low and high CF, which may have the potential to improve lesion formation and patient safety profile. In this study, CF-guided ablation did not affect AF recurrence.
BACKGROUND: The aim of this study was to evaluate the impact of contact force (CF) visualization on the incidence of low and high CF during left atrial (LA) mapping and pulmonary vein isolation (PVI). METHODS: CF was assessed in 70 patients who underwent PVI. Three highly experienced operators performed all procedures. The operators were blinded to CF in group A (35 patients), and CF was displayed in group B (35 patients). In group B, optimal CF was defined as mean CF between 10 and 39g, and operators attempted to acquire points and ablate within this range. RESULTS: A total of 8401 mapping points were analyzed during LA mapping (group A: 4104, group B: 4297). Low CF <10g and high CF ≥40g were noted in a significantly larger number of points in group A (37.7 vs. 12.0 %, P < 0.001; 11.5 vs. 1.5 %, P < 0.001). At the mitral isthmus and ridge areas, CF was significantly lower (7.7 vs. 12.2g, P < 0.001; 5.3 vs. 11.7g, P < 0.001) in group A than in group B. PVI was successfully achieved in all patients. There were significant site-dependent CF differences between the two groups. Optimal CF was achieved in significantly more applications in group B (P < 0.001). There was no significant difference in atrial fibrillation (AF) recurrence rates after a minimum follow-up of 1 year between the two groups in this cohort (P = 0.24). No significant peri-procedural complications occurred in either group. CONCLUSIONS: CF visualization can assist in avoiding both low and high CF, which may have the potential to improve lesion formation and patient safety profile. In this study, CF-guided ablation did not affect AF recurrence.
Authors: Dipen C Shah; Hendrik Lambert; Hiroshi Nakagawa; Arne Langenkamp; Nicolas Aeby; Giovanni Leo Journal: J Cardiovasc Electrophysiol Date: 2010-09
Authors: Vivek Y Reddy; Dipen Shah; Josef Kautzner; Boris Schmidt; Nadir Saoudi; Claudia Herrera; Pierre Jaïs; Gerhard Hindricks; Petr Peichl; Aude Yulzari; Hendrik Lambert; Petr Neuzil; Andrea Natale; Karl-Heinz Kuck Journal: Heart Rhythm Date: 2012-07-20 Impact factor: 6.343
Authors: Roland R Tilz; K R Julian Chun; Andreas Metzner; Andre Burchard; Erik Wissner; Buelent Koektuerk; Melanie Konstantinidou; Dieter Nuyens; Tom De Potter; Kars Neven; Alexander Fürnkranz; Feifan Ouyang; Boris Schmidt Journal: J Cardiovasc Electrophysiol Date: 2010-03-04
Authors: Alexander Fürnkranz; Julian K R Chun Julian; Boris Schmidt; Peter Wohlmuth; Roland Tilz; Karl-Heinz Kuck; Feifan Ouyang Journal: Europace Date: 2011-03-31 Impact factor: 5.214
Authors: N Sreeram; M Gass; C Apitz; G Ziemer; M Hofbeck; M Emmel; K Brockmeier; F Hitchcock; G Bennink Journal: Clin Res Cardiol Date: 2007-12-24 Impact factor: 5.460
Authors: Shouvik Haldar; Julian W E Jarman; Sandeep Panikker; David G Jones; Tushar Salukhe; Dhiraj Gupta; Gareth Wynn; Wajid Hussain; Vias Markides; Tom Wong Journal: Int J Cardiol Date: 2012-12-04 Impact factor: 4.164
Authors: Andreas Rillig; Boris Schmidt; Britta Feige; Erik Wissner; Andreas Metzner; Anita Arya; Shibu Mathew; Hisaki Makimoto; Peter Wohlmuth; Feifan Ouyang; Karl-Heinz Kuck; Roland Richard Tilz Journal: Clin Res Cardiol Date: 2013-07-30 Impact factor: 5.460
Authors: Francesco Santoro; Christian Sohns; Ardan M Saguner; Natale Daniele Brunetti; Christine Lemes; Shibu Mathew; Christian-H Heeger; Bruno Reißmann; Tilman Maurer; Johannes Riedl; Thomas Fink; Kentaro Hayashi; Feifan Ouyang; Matteo Di Biase; Karl-Heinz Kuck; Andreas Metzner Journal: Clin Res Cardiol Date: 2016-11-16 Impact factor: 5.460
Authors: Thomas Kleemann; Johannes Brachmann; Thorsten Lewalter; Dietrich Andresen; Stephan Willems; Stefan G Spitzer; Ellen Hoffmann; Lars Eckardt; Matthias Hochadel; Jochen Senges; Karl-Heinz Kuck; Karlheinz Seidl; Ralf Zahn Journal: Clin Res Cardiol Date: 2016-05-03 Impact factor: 5.460
Authors: Kristina Wasmer; Dirk G Dechering; Julia Köbe; Gerold Mönnig; Christian Pott; Gerrit Frommeyer; Philipp S Lange; Simon Kochhäuser; Lars Eckardt Journal: Clin Res Cardiol Date: 2016-04-05 Impact factor: 5.460
Authors: Tilman Maurer; Laura Rottner; Hisaki Makimoto; Bruno Reissmann; Christian-H Heeger; Christine Lemes; Thomas Fink; Johannes Riedl; Francesco Santoro; Peter Wohlmuth; Marius Volkmer; Shibu Mathew; Andreas Metzner; Feifan Ouyang; Karl-Heinz Kuck; Christian Sohns Journal: Clin Res Cardiol Date: 2018-05-08 Impact factor: 5.460
Authors: Christian Blockhaus; Jan Schmidt; Muhammed Kurt; Lukas Clasen; Patrick Müller; Christoph Brinkmeyer; Malte Kelm; Dong-In Shin; Hisaki Makimoto Journal: Arch Med Sci Date: 2016-08-23 Impact factor: 3.318